Rowlandmiller & PARTNERS.ADV Decreases Stake in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Rowlandmiller & PARTNERS.ADV reduced its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO) by 9.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 883 shares of the medical research company’s stock after selling 95 shares during the period. Rowlandmiller & PARTNERS.ADV’s holdings in Bio-Rad Laboratories were worth $295,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of the stock. UMB Bank n.a. increased its stake in shares of Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock valued at $26,000 after buying an additional 45 shares during the period. Wahed Invest LLC increased its stake in shares of Bio-Rad Laboratories by 14.0% during the first quarter. Wahed Invest LLC now owns 399 shares of the medical research company’s stock valued at $138,000 after buying an additional 49 shares during the period. Tokio Marine Asset Management Co. Ltd. increased its stake in shares of Bio-Rad Laboratories by 7.7% during the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 836 shares of the medical research company’s stock valued at $289,000 after buying an additional 60 shares during the period. Capital Advisors Ltd. LLC increased its stake in shares of Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock valued at $26,000 after buying an additional 62 shares during the period. Finally, Natixis increased its stake in shares of Bio-Rad Laboratories by 3.4% during the first quarter. Natixis now owns 1,986 shares of the medical research company’s stock valued at $687,000 after buying an additional 65 shares during the period. 65.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on BIO shares. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Citigroup raised Bio-Rad Laboratories from a “neutral” rating to a “buy” rating and upped their price target for the stock from $350.00 to $400.00 in a research note on Tuesday, October 1st. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $401.00 price target on shares of Bio-Rad Laboratories in a research note on Friday, August 16th. Finally, Wells Fargo & Company started coverage on Bio-Rad Laboratories in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price target on the stock. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $368.20.

Bio-Rad Laboratories Trading Down 2.2 %

Bio-Rad Laboratories stock opened at $327.70 on Friday. The company has a current ratio of 6.28, a quick ratio of 4.63 and a debt-to-equity ratio of 0.18. The business’s fifty day simple moving average is $331.48 and its two-hundred day simple moving average is $307.58. Bio-Rad Laboratories, Inc. has a 12 month low of $261.59 and a 12 month high of $364.24. The company has a market capitalization of $9.35 billion, a price-to-earnings ratio of -31.63 and a beta of 0.95.

Bio-Rad Laboratories (NYSE:BIO) last released its earnings results on Thursday, August 1st. The medical research company reported $3.11 EPS for the quarter, topping the consensus estimate of $2.12 by $0.99. The business had revenue of $638.50 million for the quarter, compared to the consensus estimate of $645.79 million. Bio-Rad Laboratories had a positive return on equity of 3.77% and a negative net margin of 51.73%. The company’s revenue for the quarter was down 6.3% compared to the same quarter last year. During the same period in the previous year, the company posted $3.00 earnings per share. As a group, equities analysts predict that Bio-Rad Laboratories, Inc. will post 9.45 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP James Barry sold 623 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In other news, EVP James Barry sold 623 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $330.49, for a total transaction of $205,895.27. Following the transaction, the executive vice president now directly owns 147 shares of the company’s stock, valued at $48,582.03. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Andrew J. Last sold 3,000 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $329.94, for a total value of $989,820.00. Following the sale, the chief operating officer now owns 7,559 shares of the company’s stock, valued at approximately $2,494,016.46. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.